Abstract 4143378: Polygenic Risk Stratification for Risk of Venous Thromboembolism: Analysis of >31K Individuals from the Women’s Genome Health Study and JUPITER trials

Introduction: Venous thromboembolism (VTE) carries high morbidity and mortality, highlighting the importance of early risk identification and prevention. Whether a recent polygenic risk score (PRS) could help identify those at highest risk in a longitudinal, primary prevention population is unclear. Hypothesis: PRS is an independent predictor of VTE risk in a primary prevention population. Methods: We applied the 2023 VTE PRS by Ghouse et al containing over 1 million VTE-associated SNPs to 2 primary prevention trials, JUPITER and Women’s Genome Health Study (WGHS). We calculated the adjusted hazard ratio (aHR) of VTE per 1 higher standard deviation (SD) of PRS and by risk categories: low (bottom 20%), intermediate (middle 60%), and high (top 20%) in a multivariable model adjusted for cardiovascular and demographic factors. Results: JUPITER included 8,749 participants (67.8% men, median age 66) with a median follow-up of 2.3 years and 77 VTE events (annualized event rate [ER] 0.38%). WGHS included 22,650 women (median age 53) with a median follow-up of 20.5 years and 618 VTE events (annualized ER 0.13%). Each SD increase in VTE PRS was associated with a 34% higher risk of VTE in JUPITER (aHR 1.34, 95% CI 1.08-1.67; p < 0.01) and a 61% higher risk in WGHS (aHR 1.61 (1.5-1.73; p < 0.01). Those in the high PRS category were 3.3-fold more likely to develop VTE compared to those with low PRS (JUPITER: aHR 3.30, 1.38-7.88; p < 0.01 and WGHS: 3.27, 2.44-4.38; p < 0.01) ( Fig A, B ). In comparison, Factor V and prothrombin gene mutations were associated with aHRs of 1.58 and 2.45 in JUPITER and 1.42 and 1.75 in WGHS, respectively. Additionally, the PRS predicted VTE to a similar or greater degree than established clinical risk factors. Finally, Kaplan-Meier curves demonstrated early and sustained separation in VTE events between each PRS risk group ( Fig C,D ). Conclusions: In two large primary prevention cohorts, PRS was a strong and independent predictor of VTE, with the top 20% imparting greater risk than that of established monogenic thrombophilia.

Authors

Institutions

Publication Details

Journal
Circulation
Published
2024-11-12
DOI
https://doi.org/10.1161/circ.150.suppl_1.4143378
Primary Topic
Cardiovascular Disease and Adiposity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4143378: Polygenic Risk Stratification for Risk of Venous Thromboembolism: Analysis of >31K Individuals from the Women’s Genome Health Study and JUPITER trials

Christian T. Ruff, Frederick Kamanu, Marc S. Sabatine, Giorgio Melloni et al.
Circulation
Cardiovascular Disease and Adiposity
article

Abstract 4143378: Polygenic Risk Stratification for Risk of Venous Thromboembolism: Analysis of >31K Individuals from the Women’s Genome Health Study and JUPITER trials

Christian T. Ruff, Frederick Kamanu, Marc S. Sabatine, Giorgio Melloni, Michael B. Rosamilia, Nicholas Marston, Paul M. Ridker, Daniel I. Chasman
article en

Abstract

Introduction: Venous thromboembolism (VTE) carries high morbidity and mortality, highlighting the importance of early risk identification and prevention. Whether a recent polygenic risk score (PRS) could help identify those at highest risk in a longitudinal, primary prevention population is unclear. Hypothesis: PRS is an independent predictor of VTE risk in a primary prevention population. Methods: We applied the 2023 VTE PRS by Ghouse et al containing over 1 million VTE-associated SNPs to 2 primary prevention trials, JUPITER and Women’s Genome Health Study (WGHS). We calculated the adjusted hazard ratio (aHR) of VTE per 1 higher standard deviation (SD) of PRS and by risk categories: low (bottom 20%), intermediate (middle 60%), and high (top 20%) in a multivariable model adjusted for cardiovascular and demographic factors. Results: JUPITER included 8,749 participants (67.8% men, median age 66) with a median follow-up of 2.3 years and 77 VTE events (annualized event rate [ER] 0.38%). WGHS included 22,650 women (median age 53) with a median follow-up of 20.5 years and 618 VTE events (annualized ER 0.13%). Each SD increase in VTE PRS was associated with a 34% higher risk of VTE in JUPITER (aHR 1.34, 95% CI 1.08-1.67; p < 0.01) and a 61% higher risk in WGHS (aHR 1.61 (1.5-1.73; p < 0.01). Those in the high PRS category were 3.3-fold more likely to develop VTE compared to those with low PRS (JUPITER: aHR 3.30, 1.38-7.88; p < 0.01 and WGHS: 3.27, 2.44-4.38; p < 0.01) ( Fig A, B ). In comparison, Factor V and prothrombin gene mutations were associated with aHRs of 1.58 and 2.45 in JUPITER and 1.42 and 1.75 in WGHS, respectively. Additionally, the PRS predicted VTE to a similar or greater degree than established clinical risk factors. Finally, Kaplan-Meier curves demonstrated early and sustained separation in VTE events between each PRS risk group ( Fig C,D ). Conclusions: In two large primary prevention cohorts, PRS was a strong and independent predictor of VTE, with the top 20% imparting greater risk than that of established monogenic thrombophilia.

CirculationVol. 150(Suppl_1)
Brigham and Women's Hospital (US), Mass General Brigham (US)
Good health and well-being
Openalex Percentile: Top 62%
Cardiovascular Disease and Adiposity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.